Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Fraser, Courtney
Relationship of baseline electrocardiographic characteristics with the response to cardiac resynchronization therapy for heart failure.
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Kumar, Vikas
Benefits and harms of roflumilast in moderate to severe COPD.
See All 7 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Benefits and harms of roflumilast in moderate to severe COPD.
Yu T, Fain K, Boyd CM, Singh S, Weiss CO, Li T, Varadhan R, Puhan MA. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014 Jul; 69(7):616-22.
View in:
PubMed
subject areas
Aged
Aminopyridines
Benzamides
Cyclopropanes
Female
Humans
Male
Middle Aged
Phosphodiesterase 4 Inhibitors
Placebos
Pulmonary Disease, Chronic Obstructive
Risk Assessment
authors with profiles
Sonal Singh MD, MPH